Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...